[{"id":"nct07632235","name":"A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","tldr":"A phase 1/2 trial of pembrolizumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai 6th People's Hospital, not yet recruiting.","route":"/trials/nct07632235/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07632235","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07729033","name":"A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.","tldr":"A phase 2 trial of sacituzumab tirumotecan and envafolimab in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct07729033/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07729033","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","tldr":"A phase 2 trial of durvalumab, capecitabine, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct07679399/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07679399","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."},{"label":"Ampullary cancer","href":"/cancers/ampullary/","tip":"Ampullary cancer, a biliary tract cancer, starts where the bile and pancreatic ducts empty into the small bowel. Because it blocks bile flow early it is often caught while still removable, and the Whipple operation cures a good share of patients. Tumours come in two flavours, intestinal-like and pancreas-like, and chemotherapy is increasingly chosen by which one the pathologist sees."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07623642","name":"A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by GV20 Therapeutics, not yet recruiting.","route":"/trials/nct07623642/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07623642","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06728410","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","tldr":"A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Mehmet Akce, now recruiting.","route":"/trials/nct06728410/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06728410","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Ampullary cancer","href":"/cancers/ampullary/","tip":"Ampullary cancer, a biliary tract cancer, starts where the bile and pancreatic ducts empty into the small bowel. Because it blocks bile flow early it is often caught while still removable, and the Whipple operation cures a good share of patients. Tumours come in two flavours, intestinal-like and pancreas-like, and chemotherapy is increasingly chosen by which one the pathologist sees."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07351591","name":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.","route":"/trials/nct07351591/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07351591","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","tldr":"A phase 1/2 trial of durvalumab, pembrolizumab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Yonsei University, not yet recruiting.","route":"/trials/nct07269158/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07269158","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07471165","name":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","tldr":"A phase 2 trial of the registered interventions with radiotherapy in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","route":"/trials/nct07471165/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07471165","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07099794","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","tldr":"A phase 2 trial of fluorouracil, liposomal irinotecan and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct07099794/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07099794","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06423170","name":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","tldr":"A phase 2 trial of camrelizumab, gemcitabine and oxaliplatin in gallbladder cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.","route":"/trials/nct06423170/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06423170","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07135544","name":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","tldr":"A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by Yongjun Chen, now recruiting.","route":"/trials/nct07135544/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07135544","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06654947","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","tldr":"A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and surufatinib in gallbladder cancer and other biliary tract cancers, run by Fujian Cancer Hospital, not yet recruiting.","route":"/trials/nct06654947/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06654947","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05849480","name":"A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)","tldr":"A phase 1/2 trial of oxaliplatin, capecitabine and CAPOX in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct05849480/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05849480","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02151084","name":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","tldr":"A phase 2 trial of gemcitabine, cisplatin and selumetinib in gallbladder cancer and other biliary tract cancers, run by University Health Network, Toronto, active and no longer recruiting.","route":"/trials/nct02151084/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT02151084","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06620848","name":"A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.","tldr":"A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.","route":"/trials/nct06620848/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06620848","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02632305","name":"A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","tldr":"A phase 2 trial of gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, active and no longer recruiting.","route":"/trials/nct02632305/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT02632305","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07392541","name":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","tldr":"A phase 1/2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Tongji Hospital, now recruiting.","route":"/trials/nct07392541/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07392541","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07561775","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","tldr":"A phase 2 trial of adebrelimab and S-1 in gallbladder cancer and other biliary tract cancers, run by Xingjun Guo, not yet recruiting.","route":"/trials/nct07561775/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07561775","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07296666","name":"Adjuvant Chemotherapy for BTC Based on 3D-PTA","tldr":"A phase 2 trial of capecitabine in gallbladder cancer and other biliary tract cancers, run by Fudan University, not yet recruiting.","route":"/trials/nct07296666/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07296666","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03801083","name":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Udai Kammula, active and no longer recruiting.","route":"/trials/nct03801083/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT03801083","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06638931","name":"Agnostic Therapy in Rare Solid Tumors","tldr":"A phase 2 trial of nivolumab in gallbladder cancer and other biliary tract cancers, run by Instituto do Cancer do Estado de São Paulo, now recruiting.","route":"/trials/nct06638931/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06638931","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07767994","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","tldr":"A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.","route":"/trials/nct07767994/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07767994","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07780838","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","tldr":"A phase 2 trial of durvalumab, gemcitabine, cisplatin and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Ohio State University Comprehensive Cancer Center, now recruiting.","route":"/trials/nct07780838/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07780838","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07569679","name":"Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer","tldr":"A phase 2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Air Force Military Medical University, China, now recruiting.","route":"/trials/nct07569679/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07569679","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","tldr":"A phase 2 trial of lenvatinib and ivosidenib in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct07282262/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07282262","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07668453","name":"An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies","tldr":"A phase 2 trial of adebrelimab, gemcitabine and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.","route":"/trials/nct07668453/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07668453","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06662877","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","tldr":"A phase 2/3 trial of oxaliplatin, fluorouracil, leucovorin and other drugs in gallbladder cancer and other biliary tract cancers, run by Sun Yat-sen University, not yet recruiting.","route":"/trials/nct06662877/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06662877","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of cadonilimab and anlotinib in gallbladder cancer and other biliary tract cancers, run by West China Hospital, active and no longer recruiting.","route":"/trials/nct07635290/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07635290","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05000294","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","tldr":"A phase 1/2 trial of atezolizumab and tivozanib in gallbladder cancer, run by University of Florida, now recruiting.","route":"/trials/nct05000294/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05000294","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07649980","name":"Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II","tldr":"A phase 2 trial of pucotenlimab in gallbladder cancer and other biliary tract cancers, run by HuiKai Li, not yet recruiting.","route":"/trials/nct07649980/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07649980","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07594626","name":"BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion","tldr":"A phase 1/2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Northwestern University, now recruiting.","route":"/trials/nct07594626/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07594626","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06438822","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","tldr":"A phase 2 trial of cadonilimab, fluorouracil, leucovorin and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by West China Hospital, now recruiting.","route":"/trials/nct06438822/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06438822","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06901622","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","tldr":"A phase 2 trial of camrelizumab, nab-paclitaxel, S-1 and anlotinib in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.","route":"/trials/nct06901622/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06901622","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05451290","name":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of camrelizumab, gemcitabine, oxaliplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, active and no longer recruiting.","route":"/trials/nct05451290/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05451290","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05994001","name":"Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody","tldr":"A phase 1/2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, active and no longer recruiting.","route":"/trials/nct05994001/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05994001","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06280508","name":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","tldr":"A phase 2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.","route":"/trials/nct06280508/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06280508","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06037655","name":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC","tldr":"A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","route":"/trials/nct06037655/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06037655","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07570849","name":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","tldr":"A phase 2 trial of gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.","route":"/trials/nct07570849/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07570849","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06037980","name":"CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence","tldr":"A phase 2/3 trial of gemcitabine, cisplatin, capecitabine and paclitaxel in gallbladder cancer and other biliary tract cancers, run by Gruppo Oncologico del Nord-Ovest, now recruiting.","route":"/trials/nct06037980/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06037980","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04969887","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","tldr":"A phase 2 trial of nivolumab and ipilimumab in gallbladder cancer and other biliary tract cancers, run by Olivia Newton-John Cancer Research Institute, active and no longer recruiting.","route":"/trials/nct04969887/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04969887","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05757336","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","tldr":"A phase 2 trial of sintilimab, gemcitabine, nab-paclitaxel and bevacizumab in gallbladder cancer, run by Lu Wang, MD, PhD, now recruiting.","route":"/trials/nct05757336/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05757336","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07151872","name":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and capecitabine in gallbladder cancer and other biliary tract cancers, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07151872/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07151872","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03937830","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","tldr":"A phase 2 trial of durvalumab, tremelimumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), active and no longer recruiting.","route":"/trials/nct03937830/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT03937830","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06502080","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","tldr":"A phase 2 trial of durvalumab, pembrolizumab, sintilimab and other drugs with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct06502080/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06502080","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05733000","name":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","tldr":"A phase 2 trial of gemcitabine and fluorouracil in gallbladder cancer and other biliary tract cancers, run by Northwestern University, now recruiting.","route":"/trials/nct05733000/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05733000","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07829874","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","tldr":"A phase 2 trial of lenvatinib in gallbladder cancer and other biliary tract cancers, run by Fudan University, not yet recruiting.","route":"/trials/nct07829874/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07829874","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06548412","name":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","tldr":"A phase 1/2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct06548412/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06548412","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of disitamab vedotin, pembrolizumab, camrelizumab and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, not yet recruiting.","route":"/trials/nct07159217/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07159217","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05724563","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","tldr":"A phase 2 trial of zimberelimab and domvanalimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, active and no longer recruiting.","route":"/trials/nct05724563/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05724563","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03482102","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","tldr":"A phase 2 trial of durvalumab and tremelimumab with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Massachusetts General Hospital, active and no longer recruiting.","route":"/trials/nct03482102/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT03482102","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05451043","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","tldr":"A phase 2 trial of durvalumab, tremelimumab, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, now recruiting.","route":"/trials/nct05451043/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05451043","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05640791","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","tldr":"A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct05640791/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05640791","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06490107","name":"Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC","tldr":"A phase 2 trial of durvalumab and S-1 in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, active and no longer recruiting.","route":"/trials/nct06490107/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06490107","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07636824","name":"Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study","tldr":"A phase 2 trial of capecitabine and S-1 with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct07636824/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07636824","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07638501","name":"Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer","tldr":"A phase 2 trial of sintilimab, gemcitabine and cisplatin with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.","route":"/trials/nct07638501/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07638501","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07003815","name":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Tongji Hospital, not yet recruiting.","route":"/trials/nct07003815/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07003815","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04645160","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","tldr":"A phase 1/2 trial of tivozanib in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct04645160/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04645160","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05482516","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","tldr":"A phase 3 trial of atezolizumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by Georgetown University, now recruiting.","route":"/trials/nct05482516/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05482516","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07631884","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","tldr":"A phase 2 trial of trastuzumab rezetecan in gallbladder cancer and other biliary tract cancers, run by Haihua Yuan, not yet recruiting.","route":"/trials/nct07631884/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07631884","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07105852","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","tldr":"A phase 2 trial of sacituzumab tirumotecan and pucotenlimab in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, now recruiting.","route":"/trials/nct07105852/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07105852","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07478523","name":"FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by University Hospital, Bordeaux, now recruiting.","route":"/trials/nct07478523/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07478523","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05749900","name":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","tldr":"A phase 1/2 trial of trastuzumab, nivolumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Yonsei University, now recruiting.","route":"/trials/nct05749900/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05749900","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","tldr":"A phase 2 trial of tislelizumab, gemcitabine, nab-paclitaxel and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Wei Gong, now recruiting.","route":"/trials/nct06963060/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06963060","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07310069","name":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","tldr":"A phase 2 trial of gemcitabine and nab-paclitaxel in gallbladder cancer, run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, now recruiting.","route":"/trials/nct07310069/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07310069","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06591650","name":"Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer","tldr":"A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer, run by Fudan University, now recruiting.","route":"/trials/nct06591650/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06591650","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07599995","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","tldr":"A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, not yet recruiting.","route":"/trials/nct07599995/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07599995","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07433673","name":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","tldr":"A phase 2 trial of cemiplimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Columbia University, now recruiting.","route":"/trials/nct07433673/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07433673","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of adebrelimab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Harbin Medical University, not yet recruiting.","route":"/trials/nct06389500/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06389500","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","tldr":"A phase 1/2 trial of envafolimab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by West China Hospital, now recruiting.","route":"/trials/nct07636798/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07636798","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03364530","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","tldr":"A phase 2 trial of gemcitabine and oxaliplatin in gallbladder cancer and other biliary tract cancers, run by University Hospital, Montpellier, now recruiting.","route":"/trials/nct03364530/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT03364530","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04238637","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","tldr":"A phase 2 trial of durvalumab and tremelimumab in gallbladder cancer and other biliary tract cancers, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, active and no longer recruiting.","route":"/trials/nct04238637/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04238637","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07745296","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","tldr":"A phase 3 trial of zanidatamab, capecitabine, futibatinib and ivosidenib in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.","route":"/trials/nct07745296/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07745296","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07263360","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","tldr":"A phase 2 trial of gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct07263360/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07263360","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06993025","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","tldr":"A phase 2 trial of ivonescimab, fluorouracil and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct06993025/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06993025","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05985707","name":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Peking University Cancer Hospital & Institute, not yet recruiting.","route":"/trials/nct05985707/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05985707","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05170438","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","tldr":"A phase 2 trial of gemcitabine, paclitaxel and lenvatinib in gallbladder cancer and other biliary tract cancers, run by National Health Research Institutes, Taiwan, active and no longer recruiting.","route":"/trials/nct05170438/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05170438","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06789848","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","tldr":"A phase 2 trial of cadonilimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, now recruiting.","route":"/trials/nct06789848/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06789848","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07797816","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of sintilimab, fluorouracil, leucovorin and liposomal irinotecan with radiotherapy in gallbladder cancer and other biliary tract cancers, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct07797816/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07797816","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07062536","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","tldr":"A phase 2 trial of oxaliplatin, leucovorin, FOLFOX and other drugs in gallbladder cancer and other biliary tract cancers, run by Seoul National University Bundang Hospital, now recruiting.","route":"/trials/nct07062536/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07062536","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07036380","name":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","tldr":"A phase 2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Centre Hospitalier Universitaire de Besancon, now recruiting.","route":"/trials/nct07036380/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07036380","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04910386","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","tldr":"A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by 3D Medicines (Sichuan) Co., Ltd., not yet recruiting.","route":"/trials/nct04910386/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04910386","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04005339","name":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","tldr":"A phase 2 trial of fluorouracil, leucovorin and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by Georgetown University, active and no longer recruiting.","route":"/trials/nct04005339/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04005339","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06903273","name":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","tldr":"A phase 2 trial of tislelizumab, gemcitabine, cisplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by National Cheng-Kung University Hospital, not yet recruiting.","route":"/trials/nct06903273/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06903273","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05705492","name":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by OHSU Knight Cancer Institute, now recruiting.","route":"/trials/nct05705492/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05705492","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04042831","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","tldr":"A phase 2 trial of olaparib in gallbladder cancer and other biliary tract cancers, run by Academic and Community Cancer Research United, active and no longer recruiting.","route":"/trials/nct04042831/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04042831","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct05222971","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","tldr":"A phase 2 trial of durvalumab and olaparib in gallbladder cancer and other biliary tract cancers, run by Asan Medical Center, now recruiting.","route":"/trials/nct05222971/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05222971","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","tldr":"A phase 2 trial of toripalimab, FOLFOX and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Fudan University, not yet recruiting.","route":"/trials/nct06919848/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06919848","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04634058","name":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, active and no longer recruiting.","route":"/trials/nct04634058/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04634058","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of pembrolizumab, gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct06230471/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06230471","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06530823","name":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma","tldr":"A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.","route":"/trials/nct06530823/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06530823","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07786766","name":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma","tldr":"A phase 2 trial of pemigatinib in gallbladder cancer and other biliary tract cancers, run by Haitao Zhao, MD, now recruiting.","route":"/trials/nct07786766/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07786766","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06001658","name":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","tldr":"A phase 2 trial of pembrolizumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","route":"/trials/nct06001658/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06001658","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07793253","name":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer","tldr":"A phase 2 trial of daraxonrasib in gallbladder cancer and other biliary tract cancers, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, not yet recruiting.","route":"/trials/nct07793253/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07793253","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","tldr":"A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct06852287/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06852287","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06708858","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of durvalumab, pembrolizumab, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by Dai, Guanghai, now recruiting.","route":"/trials/nct06708858/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06708858","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07530445","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","tldr":"A phase 2 trial of nab-paclitaxel and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct07530445/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07530445","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."},{"label":"Ampullary cancer","href":"/cancers/ampullary/","tip":"Ampullary cancer, a biliary tract cancer, starts where the bile and pancreatic ducts empty into the small bowel. Because it blocks bile flow early it is often caught while still removable, and the Whipple operation cures a good share of patients. Tumours come in two flavours, intestinal-like and pancreas-like, and chemotherapy is increasingly chosen by which one the pathologist sees."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","tldr":"A phase 2 trial of trastuzumab rezetecan, adebrelimab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct07670273/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07670273","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","tldr":"A phase 2 trial of trastuzumab rezetecan, adebrelimab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct07704177/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07704177","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07159204","name":"Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of paclitaxel in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, active and no longer recruiting.","route":"/trials/nct07159204/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07159204","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07729917","name":"Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","tldr":"A phase 2 trial of gemcitabine and oxaliplatin in gallbladder cancer and other biliary tract cancers, run by Zhejiang University, not yet recruiting.","route":"/trials/nct07729917/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07729917","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06892925","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","tldr":"A phase 2 trial of gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, active and no longer recruiting.","route":"/trials/nct06892925/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06892925","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07733115","name":"QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","tldr":"A phase 2 trial of gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.","route":"/trials/nct07733115/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07733115","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07701122","name":"Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of sacituzumab tirumotecan in gallbladder cancer and other biliary tract cancers, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.","route":"/trials/nct07701122/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07701122","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06274879","name":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","tldr":"A phase 2 trial of durvalumab and cisplatin in gallbladder cancer and other biliary tract cancers, run by Insel Gruppe AG, University Hospital Bern, now recruiting.","route":"/trials/nct06274879/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06274879","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07025174","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and other drugs in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, now recruiting.","route":"/trials/nct07025174/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07025174","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07654530","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","tldr":"A phase 2 trial of ipilimumab, sintilimab, gemcitabine and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, active and no longer recruiting.","route":"/trials/nct07654530/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07654530","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07831993","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","tldr":"A phase 2 trial of sintilimab, gemcitabine, cisplatin and other drugs in gallbladder cancer and other biliary tract cancers, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.","route":"/trials/nct07831993/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07831993","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07598318","name":"Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations","tldr":"A phase 2/3 trial of pucotenlimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, not yet recruiting.","route":"/trials/nct07598318/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07598318","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06048133","name":"Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)","tldr":"A phase 2 trial of zimberelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Nataliya Uboha, active and no longer recruiting.","route":"/trials/nct06048133/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06048133","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07726446","name":"Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","route":"/trials/nct07726446/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07726446","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06531291","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","tldr":"A phase 2 trial of serplulimab and surufatinib in gallbladder cancer and other biliary tract cancers, run by RenJi Hospital, not yet recruiting.","route":"/trials/nct06531291/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06531291","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04183712","name":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","tldr":"A phase 2 trial of gemcitabine, oxaliplatin and afatinib in gallbladder cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting.","route":"/trials/nct04183712/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04183712","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04941287","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","tldr":"A phase 2 trial of atezolizumab and cobimetinib in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), active and no longer recruiting.","route":"/trials/nct04941287/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04941287","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07437287","name":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","tldr":"A phase 2/3 trial of FOLFOX in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.","route":"/trials/nct07437287/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07437287","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04068194","name":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","tldr":"A phase 1/2 trial of avelumab with radiotherapy in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), active and no longer recruiting.","route":"/trials/nct04068194/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04068194","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06355427","name":"The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma","tldr":"A phase 2/3 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Mara Veenstra, MD, now recruiting.","route":"/trials/nct06355427/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06355427","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07514533","name":"The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma","tldr":"A phase 2 trial of pucotenlimab in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, not yet recruiting.","route":"/trials/nct07514533/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07514533","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07160283","name":"The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by The Second Affiliated Hospital of Shandong First Medical University, not yet recruiting.","route":"/trials/nct07160283/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07160283","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05422690","name":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","tldr":"A phase 2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Inova Health Care Services, now recruiting.","route":"/trials/nct05422690/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT05422690","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","tldr":"A phase 1/2 trial of durvalumab and regorafenib in gallbladder cancer and other biliary tract cancers, run by University of Kansas Medical Center, active and no longer recruiting.","route":"/trials/nct04781192/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT04781192","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07109167","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","tldr":"A phase 2 trial of benmelstobart, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by The Second Affiliated Hospital of Shandong First Medical University, not yet recruiting.","route":"/trials/nct07109167/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07109167","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06717464","name":"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer","tldr":"A phase 2 trial of toripalimab and capecitabine in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, active and no longer recruiting.","route":"/trials/nct06717464/","status":"active","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06717464","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07506057","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","tldr":"A phase 2 trial of trastuzumab and serplulimab in gallbladder cancer and other biliary tract cancers, run by Xiujuan Qu, now recruiting.","route":"/trials/nct07506057/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07506057","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07062263","name":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","tldr":"A phase 3 trial of trastuzumab in gallbladder cancer and other biliary tract cancers, run by Tata Memorial Centre, now recruiting.","route":"/trials/nct07062263/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07062263","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07129018","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","tldr":"A phase 2 trial of trastuzumab rezetecan, pertuzumab and trastuzumab in gallbladder cancer and other biliary tract cancers, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.","route":"/trials/nct07129018/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07129018","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07282912","name":"Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by Yale University, now recruiting.","route":"/trials/nct07282912/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07282912","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Intrahepatic cholangiocarcinoma","Extrahepatic cholangiocarcinoma","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07146646","name":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","tldr":"A phase 2 trial of oxaliplatin and trifluridine tipiracil in gallbladder cancer and other biliary tract cancers, run by Case Comprehensive Cancer Center, now recruiting.","route":"/trials/nct07146646/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07146646","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer","Ampullary cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."},{"label":"Ampullary cancer","href":"/cancers/ampullary/","tip":"Ampullary cancer, a biliary tract cancer, starts where the bile and pancreatic ducts empty into the small bowel. Because it blocks bile flow early it is often caught while still removable, and the Whipple operation cures a good share of patients. Tumours come in two flavours, intestinal-like and pancreas-like, and chemotherapy is increasingly chosen by which one the pathologist sees."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06135896","name":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by National Cancer Center, Korea, now recruiting.","route":"/trials/nct06135896/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT06135896","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07267078","name":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","tldr":"A phase 2 trial of gemcitabine and oxaliplatin in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct07267078/","status":"recruiting","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07267078","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07472933","name":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","tldr":"A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by West China Hospital, not yet recruiting.","route":"/trials/nct07472933/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07472933","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07723534","name":"Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers","tldr":"A phase 2 trial of FOLFOX and CAPOX in gallbladder cancer and other biliary tract cancers, run by Midhun Malla, not yet recruiting.","route":"/trials/nct07723534/","status":"planned","kind":"trial","cancerIcon":"gallbladder","sub":"NCT07723534","facets":{"kind":["Trial"],"cancers":["Gallbladder cancer","Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}}]